In vivo imaging of adenosine A2A receptors in rat and primate brain using [11C]SCH442416

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 32, Issue 4, 2005, Pages 405-413

  Moresco, R M ^a,b   Todde, S ^a   Belloli, S ^a   Simonelli, P ^a   Panzacchi, A ^a   Rigamonti, M ^a   Galli Kienle, M ^a   Fazio, F ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

11C SCH442416; Adenosine A2A receptor antagonist; Inhibition; PET; Striatum

Indexed keywords

3 (2 FLUOROETHYL)SPIPERONE; 4 AMINOBUTYRIC ACID RECEPTOR; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 5 AMINO 2 (2 FURYL) 7 [3 (4 METHOXYPHENYL)PROPYL]PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR ANTAGONIST; ADENOSINE RECEPTOR; CAFFEINE; DOPAMINE RECEPTOR; DRUG METABOLITE; ISTRADEFYLLINE; NEUROTOXIN; QUINOLINIC ACID; SCH 442416 C 14; TRACER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; BRAIN REGION; CELL COUNT; CEREBELLUM; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORPUS STRIATUM; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG BINDING; DRUG BRAIN LEVEL; DRUG DEGRADATION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ISOLATION; DRUG METABOLISM; DRUG SCREENING; DRUG UPTAKE; IMAGE ANALYSIS; IMAGING; IN VIVO STUDY; INHIBITION KINETICS; INJECTION; MACACA; MALE; MONKEY; NONHUMAN; PLASMA; POSITRON EMISSION TOMOGRAPHY; PRIMATE; PROTEIN EXPRESSION; RADIOACTIVITY; RAT; SIGNAL NOISE RATIO; TIME;

ANIMALS; BRAIN DISEASES; CARBON RADIOISOTOPES; CORPUS STRIATUM; MACACA NEMESTRINA; MALE; METABOLIC CLEARANCE RATE; PYRAZOLES; PYRIMIDINES; QUINOLINIC ACID; RADIOPHARMACEUTICALS; RATS; RECEPTOR, ADENOSINE A2A; SPECIES SPECIFICITY; TISSUE DISTRIBUTION;

EID: 17844371752     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-004-1688-5     Document Type: Article

References (26)

1. Latini S, Pedata F. Adenosine in the central nervous system: release mechanisms and extracellular concentrations. J Neurochem 2001;79(3):463-84.
2. Dunwiddie TV, Masino SA. The role and regulation of adenosine in the central nervous system. Annu Rev Neurosci 2001;24:31-55.
3. Fredholm BB, Arslan G, Halldner L, Kull B, Schulte G, Wasserman W. Structure and function of adenosine receptors and their genes. Naunyn Schmiedebergs Arch Pharmacol 2000;362(4-5):364-74.
4. 2A receptors. Trends Pharmacol Sci 1996;17(10):364-72.
5. 2a receptors in the rat hippocampus. Brain Res 1994;649(1-2):208-16.
6. 2A receptors. Prog Neurobiol 1999;59(4):355-96.
7. Ferre S, Fredholm BB, Morelli M, Popoli P, Fuxe K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci 1997;20(10):482-7.
8. Fuxe K, Stromberg I, Popoli P, Rimondini-Giorgini R, Torvinen M, Ogren SO, et al. Adenosine receptors and Parkinson's disease. Relevance of antagonistic adenosine and dopamine receptor interactions in the striatum. Adv Neurol 2001;86:345-53.
9. 2A receptor blockade in experimental models of Parkinson's disease. J Neurochem 2002;80(2):262-70.
10. Abbracchio MP, Cattabeni F. Brain adenosine receptors as targets for therapeutic intervention in neurodegenerative diseases. Ann N Y Acad Sci 1999;890:79-92.
11. 2a receptor. Nature 1997;388(6643):674-8.
12. 2A receptor knockout mice. Br J Pharmacol 2001;134(1):68-77.
13. Moresco RM, Messa C, Lucignani G, Rizzo GG, Todde S, Carla Gilardi M, et al. PET in psychopharmacology. Pharmacol Res 2001;44(3):151-9.
14. 2a receptor ligand. J Nucl Med 2000;41(2):345-54.
15. Todde S, Moresco RM, Simonelli P, Baraldi PG, Cacciari B, Spalluto G, et al. Design, radiosynthesis, and biodistribution of a new potent and selective ligand for in vivo imaging of the adenosine A(2A) receptor system using positron emission tomography. J Med Chem 2000;43(23):4359-62.
16. Levivier M, Holemans S, Togasaki DM, Maloteaux JM, Brotchi J, Przedborski S. Quantitative assessment of quinolinic acid-induced striatal toxicity in rats using radioligand binding assays. Neurol Res 1994;16(3):194-200.
17. Levivier M, Przedborski S. Quinolinic acid-induced lesions of the rat striatum: quantitative autoradiographic binding assessment. Neurol Res 1998;20(1):46-56.
18. Belloli S, Moresco RM, Matarrese M, Biella G, Sanvito F, Simonelli P, et al. Evaluation of three quinoline-carboxamide derivatives as potential radioligands for the in vivo PET imaging of neurodegeneration. Neurochem Int 2004;44(6):433-40.
19. Paxinos G, Watson C. The rat brain in stereotaxic coordinates, 4th edn. New York: Academic Press; 1998.
20. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage 1996;4(3 Pt 1):153-8.
21. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage 1997;6(4):279-87.
22. Press WH, Flannery BP, Teukolsky SA, Vetterling WT. Numerical recipes. The art of scientific computing. New York, Cambridge: Cambridge University Press; 1986.
23. 11C]KF18446 PET in the rat brain after quinolinic acid lesion: comparison with the dopamine receptor imaging. Ann Nucl Med 2002;16(7):467-75.
24. 3H]SCH 58261. Eur J Neurosci 2001;14(9):1567-70.
25. 2a receptor ligand. J Nucl Med 1998;39(3):498-503.
26. Wang WF, Ishiwata K, Nonaka H, Ishii S, Kiyosawa M, Shimada J, et al. Carbon-11-labeled KF21213: a highly selective ligand for mapping CNS adenosine A(2A) receptors with positron emission tomography. Nucl Med Biol 2000;27(6):541-6.